Pre-commercial procurement for integrated CARE solutions addressing the Multimorbidity mATRIX in ageing populations

Over 50m people suffer from multimorbidity (PMM) in Europe. Recent reviews find that PMM experience a range of system and professional-related issues with care delivery.

In part, this is because current investments in process-based delivery means delivering healthcare within single diagnoses tracks/silos.

For PMMs this does not reflect real-world conditions.No technology is available today that enables the specific care, treatment, administration and support needed for this target group. Breakthrough solutions will classify the individual according to their co/multimorbidities and medications.

But this needs to be developed in close dialogue between PMM, care providers and industry sectors based upon a strong demand driven approach in a PCP.Accordingly, the CareMatrix Buyers Group (SE, NO, ES) challenge the market to develop innovative technology that enables more predictive care and support benefits for PMM.

This is achieved with 6 project objectives summarised as PCP: stakeholder engagement, roadmap, Call, implementation, next steps and; profiling and outreach via IFIC.The methodology can be summarised as PCP: framing actions (PCP preparation, use of UCD principles and practice); implementation actions (Phases 1-3 contract management, support, evaluation and testing) and Market Preparation actions (business development support for Phase 3 suppliers, standards, initial PPI preparation).Direct benefits include:• 20% reduction in time spent for visits to care facilities• Improvements from baseline in at least 75% of aspects of care as identified using PREM surveys• 50% fewer patient data-related incidents (increased patient safety) between organizations • No of clinical errors reduced by 30%;Underpinning the CareMatrix solution(s) with integrated innovation (supportive policy priorities, organisational and social innovations) will optimise the potential of those solutions to produce savings of 10% in health care expenditure for PMM.